Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
{{output}}
Belantamab mafodotin (belamaf) is an antibody-drug conjugate targeting B-cell maturation antigen on plasma cells. The phase III DREAMM-7 and DREAMM-8 trials, in which belamaf was combined with bortezomib-dexamethasone or pomalidomide-dexamethasone, respectivel... ...
